睾酮治疗预防或逆转男性2型糖尿病(T4DM):随机双盲安慰剂对照2年3b期试验
BACKGROUND: Men who are overweight or obese frequently have low serum testosterone concentrations, which are associated with increased risk of type 2 diabetes.…
要点
- 在生活方式干预基础上,睾酮治疗2年可降低糖耐量受损或早期2型糖尿病男性的糖尿病发生比例。
- 睾酮组血细胞比容>54%的安全触发更常见(22% vs 1%),可能限制治疗。
- 疗效与基线血清睾酮水平无关,长期安全性及心血管影响尚待研究。
核心结论
- 疗效独立于基线血清睾酮水平;血细胞比容升高可能限制治疗,长期耐久性、安全性和心血管效应待进一步研究。
研究设计与样本
- T4DM为随机、双盲、安慰剂对照、2年、3b期试验,在澳大利亚6个三级中心开展。
- 受试者均参加生活方式项目,按1:1随机接受睾酮十一酸酯1000 mg或安慰剂肌注,基线、6周后每3个月一次,共2年。
- 预筛19 022人,随机1007人(5%),安慰剂组503例、睾酮组504例;主要结局按意向治疗分析。
主要发现
- 血细胞比容>54%的安全触发:安慰剂组484例中6例(1%),睾酮组491例中106例(22%)。
关键数值与推荐
- 干预剂量:睾酮十一酸酯1000 mg肌注,基线、6周及之后每3个月一次,共2年。
临床怎么用
- 对超重或肥胖、睾酮偏低且糖耐量受损或早期2型糖尿病的50-74岁男性,可在生活方式干预基础上考虑睾酮治疗以降低糖尿病风险。
- 治疗期间需监测血细胞比容,>54%可能需限制治疗,并监测前列腺特异性抗原。
- 疗效不依赖基线睾酮水平,患者选择不能仅依据睾酮高低;长期心血管安全性未确定,需个体化评估。
局限性
- 研究仅纳入50-74岁男性,结论不能外推至女性、年轻男性或其他人群。
- 2年干预期,长期耐久性、安全性和心血管效应尚未确定。
- 血细胞比容升高可能限制治疗,需进一步评估管理策略。
- 部分结局存在数据缺失(如2年OGTT可评估者少于随机人数)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men who are overweight or obese frequently have low serum testosterone concentrations, which are associated with increased risk of type 2 diabetes. We aimed to determine whether testosterone treatment prevents progression to or reverses early type 2 diabetes, beyond the effects of a community-based lifestyle programme. METHODS: T4DM was a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial done at six Australian tertiary care centres. Men aged 50-74 years, with a waist circumference of 95 cm or higher, a serum testosterone concentration of 14·0 nmol/L or lower but without pathological hypogonadism, and impaired glucose tolerance (oral glucose tolerance test [OGTT] 2-h glucose 7·8-11·0 mmol/L) or newly diagnosed type 2 diabetes (provided OGTT 2-h glucose ≤15·0 mmol/L) were enrolled in a lifestyle programme and randomly assigned (1:1) to receive an intramuscular injection of testosterone undecanoate (1000 mg) or placebo at baseline, 6 weeks, and then every 3 months for 2 years. Randomisation was done centrally, including stratification by centre, age group, waist circumference, 2-h OGTT glucose, smoking, and first-degree family history of type 2 diabetes. The primary outcomes at 2 years were type 2 diabetes (2-h OGTT glucose ≥11·1 mmol/L) and mean change from baseline in 2-h OGTT glucose, assessed by intention to treat. For safety assessment, we did a masked monitoring of haematocrit and prostate-specific antigen, and analysed prespecified serious adverse events. This study is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12612000287831. FINDINGS: Between Feb 5, 2013, and Feb 27, 2017, of 19 022 men who were pre-screened, 1007 (5%) were randomly assigned to the placebo (n=503) and testosterone (n=504) groups. At 2 years, 2-h glucose of 11·1 mmol/L or higher on OGTT was reported in 87 (21%) of 413 participants with available data in the placebo group and 55 (12%) of 443 participants in the testosterone group (relative risk 0·59, 95% CI 0·43 to 0·80; p=0·0007). The mean change from baseline 2-h glucose was -0·95 mmol/L (SD 2·78) in the placebo group and -1·70 mmol/L (SD 2·47) in the testosterone group (mean difference -0·75 mmol/L, -1·10 to -0·40; p<0·0001). The treatment effect was independent of baseline serum testosterone. A safety trigger for haematocrit greater than 54% occurred in six (1%) of 484 participants in the placebo group and 106 (22%) of 491 participants in the testosterone group, and a trigger for an increase of 0·75 μg/mL or more in prostate-specific antigen occurred in 87 (19%) of 468 participants in the placebo group and 109 (23%) of 480 participants in the testosterone group. Prespecified serious adverse events occurred in 37 (7·4%, 95% CI 5·4 to 10·0) of 503 patients in the placebo group and 55 (10·9%, 8·5 to 13·9) of 504 patients in the testosterone group. There were two deaths in each group. INTERPRETATION: Testosterone treatment for 2 years reduced the proportion of participants with type 2 diabetes beyond the effects of a lifestyle programme. Increases in haematocrit might be treatment limiting. Longer-term durability, safety, and cardiovascular effects of the intervention remain to be further investigated. FUNDING: Australian National Health and Medical Research Council, Bayer, Eli Lilly, University of Adelaide, and WW (formerly Weight Watchers).
引用
- Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021. PMID: 33338415. doi:10.1016/S2213-8587(20)30367-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。